THYMOPENTIN THERAPY REDUCES THE CLINICAL SEVERITY OF ATOPIC-DERMATITIS
THYMOPENTIN THERAPY REDUCES THE CLINICAL SEVERITY OF ATOPIC-DERMATITIS
复制标题
DOI：
10.1016/0091-6749(90)90079-j
复制
发表时间：
1990-05-01
影响因子：
14.2
通讯作者：
HANIFIN, JM
中科院分区：
文献类型：
--
作者：
LEUNG, DYM;HIRSCH, RL;HANIFIN, JM
100名中到重度特应性皮炎患者参加了一项双中心、双盲试验。患者随机接受胸腺五肽(Timunox，n=48)或安慰剂(n=52)，作为每日皮下注射，持续6周。在研究期间，在基线和定期时间间隔测量疾病的临床程度和严重程度参数。服用安慰剂和服用胸腺五肽的两组患者的总体病情严重程度均呈进行性和统计学意义上的下降(p<；0.001)，但在治疗6周后，服用胸腺五肽的患者组的临床严重程度评分下降幅度更大，与服用安慰剂的对照组相比有统计学意义(p=0.04)。当胸腺五肽治疗与安慰剂治疗相比时，包括总严重程度评分的个别症状中，瘙痒(p=0.02)和红斑(p=0.04)显著减少。此外，与安慰剂组相比，胸腺五肽治疗组在6周后身体受累的程度和严重程度指数(综合严重程度/程度指数)都显著降低(p=0.04)。两组患者均未出现严重不良反应。我们得出结论，胸腺五肽的治疗是安全的，并为特应性皮炎提供了显著的治疗前景。
One hundred patients with moderate to severe atopic dermatitis were entered into a two-center, double-blind trial. Patients were randomized to receive either thymopentin (Timunox, n = 48) or placebo (n = 52), administered as daily subcutaneous injections for 6 weeks. Clinical extent of disease and severity parameters were measured at baseline and at regular time intervals during the study. Both the placebo- and thymopentin-treated groups demonstrated a progressive and statistically significant (p < 0.001) decline in the overall severity of their disease, but reduction in the clinical severity score was higher in the thymopentin-treated group and statistically significant (p = 0.04) in comparison with the placebo-treated group after 6 weeks of treatment. Of the individual symptoms comprising the total severity score, pruritis (p = 0.02) and erythema (p = 0.04) were reduced significantly when thymopentin therapy was compared to placebo therapy. In addition, both the extent of body involvement and severity index (a combined severity/extent index) were significantly reduced after 6 weeks in the thymopentin-treated group in comparison to the placebo-treated group (p = 0.04). There were no serious adverse experiences in either treatment group. We conclude that treatments with thymopentin is safe and offers significant therapeutic promise for atopic dermatitis.